Peer Review reports
From: Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China
| Original Submission | ||
|---|---|---|
| 6 Sep 2017 | Submitted | Original manuscript |
| 25 Sep 2017 | Reviewed | Reviewer Report - Samuel Kerk |
| 30 Oct 2017 | Author responded | Author comments - Lu Xie |
| Resubmission - Version 2 | ||
| 30 Oct 2017 | Submitted | Manuscript version 2 |
| 28 Dec 2017 | Reviewed | Reviewer Report - Stephen Weiss Lab |
| 21 Jan 2018 | Author responded | Author comments - Lu Xie |
| Resubmission - Version 3 | ||
| 21 Jan 2018 | Submitted | Manuscript version 3 |
| 19 Mar 2018 | Author responded | Author comments - Lu Xie |
| Resubmission - Version 4 | ||
| 19 Mar 2018 | Submitted | Manuscript version 4 |
| 22 Mar 2018 | Author responded | Author comments - Lu Xie |
| Resubmission - Version 5 | ||
| 22 Mar 2018 | Submitted | Manuscript version 5 |
| Publishing | ||
| 26 Mar 2018 | Editorially accepted | |
| 6 Apr 2018 | Article published | 10.1186/s12885-018-4303-z |
You can find further information about peer review here.